How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

37 results for

Mestinon

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis

Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect (...) of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03510546 Recruitment Status : Recruiting First Posted : April 27, 2018 Last Update Posted : April 27, 2018 See

2018 Clinical Trials

2. Mestinon

Mestinon Mestinon Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Mestinon Mestinon Aka: Mestinon II. Indications III. Components (...) Neostigmine IV. Mechanism medications V. Dosing Mestinon 60-120 mg every 3-4 hours Doses exceeding 120 mg q3 hours are not more effective VI. Adverse effects (Especially at higher dose) Gastrointestinal side effects Muscle Fasciculations Eye tearing VII. Efficacy Not often effective as monotherapy in Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Mestinon." Click on the image (or right click) to open the source website in a new

2018 FP Notebook

3. Leukocytoclastic Vasculitis Secondary to Pyridostigmine (Mestinon): Report of a Possible First Case Full Text available with Trip Pro

Leukocytoclastic Vasculitis Secondary to Pyridostigmine (Mestinon): Report of a Possible First Case Pyridostigmine is an acetylcholinesterase inhibitor commonly used in the treatment of myasthenia gravis. We describe a patient who developed a rash after recently being started on pyridostigmine and give a general review of leukocytoclastic vasculitis.A 91-year-old man was diagnosed with ocular myasthenia gravis. He was started on pyridostigmine, and 2 weeks later he developed a rash. The rash

2016 The Permanente journal

4. Mestinon

Mestinon Mestinon Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Mestinon Mestinon Aka: Mestinon II. Indications III. Components (...) Neostigmine IV. Mechanism medications V. Dosing Mestinon 60-120 mg every 3-4 hours Doses exceeding 120 mg q3 hours are not more effective VI. Adverse effects (Especially at higher dose) Gastrointestinal side effects Muscle Fasciculations Eye tearing VII. Efficacy Not often effective as monotherapy in Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Mestinon." Click on the image (or right click) to open the source website in a new

2015 FP Notebook

5. Mestinon (Pyridostigmine Bromide) in Myasthenia Gravis Full Text available with Trip Pro

Mestinon (Pyridostigmine Bromide) in Myasthenia Gravis 13343058 2003 05 01 2018 12 01 0008-4409 75 2 1956 Jul 15 Canadian Medical Association journal Can Med Assoc J Mestinon (pyridostigmine bromide) in myasthenia gravis. 98-100 SCHWARZ H H eng Journal Article Canada Can Med Assoc J 0414110 0008-4409 0 Parasympathomimetics 8063-06-7 Curare KVI301NA53 Pyridostigmine Bromide OM Curare antagonists & inhibitors Myasthenia Gravis therapy Parasympathomimetics therapeutic use Pyridostigmine Bromide

1956 Canadian Medical Association Journal

6. An association of myasthenia gravis with Hashimoto's thyroiditis in a patient with a multinodular goitre Full Text available with Trip Pro

hyperthyroidism secondary to Hashimoto's thyroiditis in multinodular goitre was diagnosed with generalised MG after 2 years. She presented with right eye ptosis (ocular) and difficulty in swallowing and chewing (bulbar). The diagnosis of MG was confirmed by fatigability testing, electromyography and the presence of AChR antibodies. Her symptoms showed improvement with pyridostigmine (Mestinon) 60 mg 6-hourly. Her antithyroid drug was tapered down according to her thyroid function test. Throughout a year

2017 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

7. Neostigmine Methylsulfate Injection, USP

secretions, and other parasympathomimetic side effects, which are reduced or prevented by the inclusion of atropine sulfate in the drug product. Atropine sulfate has an immediate effect on heart rate which reaches a peak in 2 to 16 minutes following intravenous administration and lasts 170 minutes after an average 0.02 mg/kg dose. Pyridostigmine is another anticholinesterase product. It was first approved as Mestinon (NDA 009830) in 1955, and later approved as Regonol (NDA 017398). Mestinon is used most

2014 FDA - Drug Approval Package

8. Orthostatic Hypotension Management

: Used in DM, pure autonomic failure, multiple system atrophy. More effective with midodrine than either drug if used alone. Costly; SC or IV. Pyridostigmine MESTINON: 30mg BID-TID, ? to 60mg TID. Some success in autonomic failure. Not studied in older/complex medical patients. Nitroglycerin patch: if supine HTN, nighttime dosing 8pm-8am used for nighttime congestion Dihydroxyphenylserine DROXIDOPA: 100-600mg TID, 100, 200, 300 mg FDA’2014. N/A Canada Other Considerations: ? Antihypertensives should

2014 RxFiles

9. Pyridostigmine as Immunomodulator in People Living With HIV

(Mestinon®), an acetylcholinesterase inhibitor (ACh-E), in HIV-infected patients. We observed that administration of pyridostigmine decreases the activation and proliferation of HIV-infected T cells, reduces the production of interferon (IFN) -gamma and increases that of interleukin (IL) -10 (Valdés-Ferrer SI et al., AIDS Research And Human Retrovir 2009). In a second open-label pilot study in seven chronically infected patients with full virological suppression but without concomitant elevation of CD4 (...) inflammation. Since cholinergic agonists are rapidly degraded or cause side effects, we performed a pilot study using pyridostigmine (Mestinon®), an acetylcholinesterase inhibitor (ACh-E), in HIV-infected patients. We observed that administration of pyridostigmine decreases the activation and proliferation of HIV-infected T cells, reduces the production of interferon (IFN) -gamma and increases that of interleukin (IL) -10 (Valdés-Ferrer SI et al., AIDS Research And Human Retrovir 2009). In a second open

2017 Clinical Trials

10. Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS

: Pyridostigmine 60mg by mouth Other Name: Mestinon Drug: Placebo Lactulose 50mg by mouth Active Comparator: Digoxin and Placebo Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day Drug: Digoxin 0.5 (500mcg) by mouth Drug: Placebo Lactulose 50mg by mouth Outcome Measures Go to Primary Outcome Measures : Cardiovagal Baroreflex during orthostatic stress [ Time Frame: 1 year ] Cardiovagal Baroreflex during orthostatic stress in unmedicated POTS patients compared (...) Stewart, New York Medical College: Postural Orthostatic Tachycardia Syndrome (POTS) POTS Orthostatic Intolerance Digoxin Pyridostigmine Mestinon Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Tachycardia Orthostatic Intolerance Postural Orthostatic Tachycardia Syndrome Disease Pathologic Processes Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Cardiac Conduction System Disease Primary Dysautonomias Autonomic Nervous System Diseases Nervous System Diseases Neurologic

2017 Clinical Trials

11. AchE Inhibitor and Insulin

with pyridostigmine An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg Drug: Pyridostigmine single oral dose of 60 mg pyridostigmine tablet Other Name: Mestinon Outcome Measures Go to Primary Outcome Measures : First phase insulin response to IV glucose infusion [ Time Frame: -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes ] Insulin positive incremental area under the curve and the sum of plasma insulin values at 1 minute and 3 minutes after IV glucose infusion Secondary Outcome

2017 Clinical Trials

12. Vagal Stimulation in POTS

/sham stimulation Patients will receive a single oral dose of pyridostigmine pill 30 mg, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation Drug: Pyridostigmine Pill pyridostigmine bromide 30 mg single oral dose Other Names: pyridostigmine bromide Mestinon Device: Vagal stimulation Vagal stimulation will be given at 50 Hz during the tilt table tests Other Name: Transcutaneous vagal nerve stimulation Device: Sham vagal stimulation

2017 Clinical Trials

13. Autonomic Neuropathy, GI Motility, and Inflammation in HIV

Bromide Mestinon Regonol Gravitor Outcome Measures Go to Primary Outcome Measures : vagal sub-score [ Time Frame: baseline ] vagal sub-score of the composite autonomic scoring scale (mCASS) assessing vagal dysfunction,calculated from autonomic testing. the heart rate response to deep breathing and the Valsalva ratio. Secondary Outcome Measures : Gastric Emptying (GE T 1/2) [ Time Frame: week 8 ] GI dysmotility calculated from gastric emptying scintigraphy - measurement of the time required

2016 Clinical Trials

14. SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4

Details Study Description Go to Brief Summary: A trial investigating the effects of pyridostigmine (mestinon) versus a placebo in a double-blind cross over trial in patients with hereditary proximal spinal muscular atrophy (SMA) types 2, 3 and 4. Condition or disease Intervention/treatment Phase Spinal Muscular Atrophy SMA Kugelberg-Welander Disease Drug: Pyridostigmine Drug: Placebo Phase 2 Detailed Description: In this cross-over trial we will investigate the effects of pyridostigmine (mestinon (...) ) versus a placebo on fatigability in patients with hereditary proximal spinal muscular atrophy (SMA) types 2, 3 and 4 (aged 12 and older) The study participants will be using a placebo during 8 weeks and mestinon during 8 weeks. Both investigators and patients are blinded to the treatment allocation in both periods. Patients will be randomly assigned to use placebo or mestinon first. At the end of the study, patients will have used both mestinon and a placebo during 8 weeks. In both phases (periods

2016 Clinical Trials

15. A Pilot Study of Pyridostigmine in Pompe Disease

will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm. Drug: Pyridostigmine Bromide Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup. Other Name: Mestinon Experimental: Prolonged Use of Pyridostigmine (...) weekly via telephone. All study subjects will be enrolled in this arm. Drug: Pyridostigmine Bromide Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup. Other Name: Mestinon Outcome Measures Go to Primary Outcome Measures : Change in skeletal muscle function (6 Minute Walk Test)(QMT) [ Time Frame: Baseline, Day 90 ] Quantitative muscle testing and the 6 Minute Walk

2015 Clinical Trials

17. Acetylcholinesterase Inhibition and Orthostatic Hypotension in SC I

position for an additional 30 minutes until the tilting protocol commences. Drug: Pyridostigmine Bromide After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences. Other Name: Brand Name: Mestinon Device: Tilt table

2014 Clinical Trials

18. Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3

Experimental: significant decrement Patients with significant decrement at electromyogram will be treated by pyridostigmine bromide 60mg 3 times a day for patients older than 18 and 1.5mg/kg 3 times a day for children less than 40kg Drug: Pyridostigmine Bromide Other Name: Mestinon No Intervention: no decrement Patient without significant decrement will not receive any treatment and will be the control group Outcome Measures Go to Primary Outcome Measures : Change from Baseline in the distance walked at 6

2014 Clinical Trials

19. Assessment of Neuromuscular Transmission (Overview)

of ptosis. Patients who do not respond to Tensilon may respond to intramuscular (Prostigmin), which has a longer duration of action. This is particularly useful in infants and children, whose response to Tensilon may be too brief for adequate observation. Neostigmine inhibits the destruction of acetylcholine by acetylcholinesterase, which facilitates transmission of impulses across the myoneural junction. In some, a therapeutic trial of oral (Mestinon, Timespan, Regonol) for several days may produce

2014 eMedicine.com

20. Assessment of Neuromuscular Transmission (Follow-up)

of ptosis. Patients who do not respond to Tensilon may respond to intramuscular (Prostigmin), which has a longer duration of action. This is particularly useful in infants and children, whose response to Tensilon may be too brief for adequate observation. Neostigmine inhibits the destruction of acetylcholine by acetylcholinesterase, which facilitates transmission of impulses across the myoneural junction. In some, a therapeutic trial of oral (Mestinon, Timespan, Regonol) for several days may produce

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>